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Leucine-rich repeat and ﬁbronectin type III domain-containing (LRFN) family proteins are thought
to be neuronal-speciﬁc proteins that play essential roles in neurite outgrowth and synapse forma-
tion. Here, we focused on expression and function of LRFN4, the fourth member of the LRFN family,
in non-neural tissues. We found that LRFN4 was expressed in a wide variety of cancer and leukemia
cell lines. We also found that expression of LRFN4 in the monocytic cell line THP-1 and in primary
monocytes was upregulated following macrophage differentiation. Furthermore, we demonstrated
that LRFN4 signaling regulated both the transendothelial migration of THP-1 cells and the elonga-
tion of THP-1 cells via actin cytoskeleton reorganization. Our data indicate that LRFN4 signaling
plays an important role in the migration of monocytes/macrophages.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Leucine-rich repeat and ﬁbronectin type III domain-containing
(LRFN) family proteins are a class of type I transmembrane (TM)
glycoproteins with ﬁve members, LRFN1–5 [1]. All members of
the LRFN family contain extracellular leucine-rich repeats (LRRs),chemical Societies. Published by E
ECs, human umbilical vein
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edical University, Nishishinj-an immunoglobulin C2-like (IgC2) domain, a ﬁbronectin type III
(FNIII) domain, a TM domain, and a cytoplasmic C-terminal tail
[1]. LRFN1, 2, and 4 contain a C-terminal postsynaptic density
95/discs large/zona occuludin-1 (PDZ)-binding domain that plays
essential roles in cellular response via association with the post-
synaptic density 95 family proteins [1–4]. Moreover, LRFN family
proteins form heteromeric and homomeric complexes in heterolo-
gous cells [5]. The expression of LRFN family members is largely re-
stricted to neural tissue, and the family members play essential
roles in neurite outgrowth and synapse formation [1–4]. However,
little is known about the expression and function of LRFN family
members in non-neural tissues.
Monocytes and macrophages play important roles in immune
responses and tissue remodeling and repair [6]. They phagocytose
cellular debris and pathogens and stimulate lymphocytes and
other immune cells to respond to pathogens. In response to inﬂam-
mation, circulating monocytes in blood vessels adhere to and sub-
sequently migrate into the endothelium; the monocytes then move
into sites of infected tissue [7–11]. After migration, monocytes dif-
ferentiate into a variety of tissue-resident macrophages [6].
Although the mechanism of monocyte/macrophage migration is
not fully understood, selectin family members, integrin family
members, and a number of chemokines contribute to this migra-
tion [7–11].lsevier B.V. All rights reserved.
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the fourth member of the LRFN family, in non-neural tissues. We
found that LRFN4 was expressed in a wide variety of human cancer
and leukemia cell lines. We also demonstrated that LRFN4 expres-
sion in monocytic cells was upregulated following macrophage dif-
ferentiation and that LRFN4 signaling played an important role in
the migration of monocytes/macrophages.2. Materials and methods
2.1. Reagents and antibodies
Dulbecco’s modiﬁed Eagle’s medium (DMEM), RPMI-1640 med-
ium, phorbol 12-myristate 13-acetate (PMA), macrophage-colony
stimulating factor, gelatin, bovine serum albumin (BSA), and
Latrunculin A were purchased fromWako Pure Chemical Industries
(Osaka, Japan). Fetal bovine serum (FBS) was purchased from Nic-
hirei Biosciences Inc. (Tokyo, Japan). Endothelial Cell Growth Med-
ium V2 was purchased from Cell Applications Inc. (San Diego, CA).
Puromycin, Protease Inhibitor Cocktail, and polybrene were pur-
chased from Sigma–Aldrich (St. Louis, MO). Brasticidine and Pro-
Long Gold Antifade Reagent were purchased from Life
Technologies (Carlsbad, CA). Ficoll-Paque Plus was purchased from
GE Healthcare UK Ltd. (Amersham Place, Buckinghamshire, UK).
Interleukin-1b (IL-1b) was purchased from PeproTech (Rocky Hill,
NJ). TransFast transfection reagent was purchased from Promega
(Madison, WI). Immobilon Western Chemiluminescent HRP Sub-
strate was purchased from Millipore (Billerica, MA). Mouse anti-
LRFN4 monoclonal antibodies (mAbs) clone 3A12-7 and 3H12A
were generated by ACTGen, as described in Supplementary mate-
rial (Section S2.2). Anti-b-actin mAb (clone AC-15), anti-FLAG
mAb (clone M2) and rhodamine-conjugated phalloidin were pur-
chased from Sigma–Aldrich. Mouse IgG2 isotype control antibody
was purchased from R&D Systems (Minneapolis, MN). Horseradish
peroxidase-conjugated horse anti-mouse IgG was purchased from
Vector Laboratories (Burlingame, CA). Alexa Fluor 488-conjugated
donkey anti-mouse IgG was purchased from Life Technologies.
Hoechst 33342 was purchased from Dojindo Laboratories (Kuma-
moto, Japan).
2.2. Plasmid construction
Retrovirus vector pMYs-IG and pMYs were kindly provided by
Prof. Toshio Kitamura at the University of Tokyo. The cDNA encod-
ing the entire open-reading frame of the human LRFN4 gene (Gen-
Bank ID: NM_024036) was ampliﬁed by PCR from ﬁrst strand cDNA
of PANC-1 cells. To generate the pMYs-LRFN4-GFP plasmid, the
ampliﬁed LRFN4 fragment was subcloned into BamHI/NcoI sites
of pMYs-IG in-frame with the vector’s C-terminal EGFP sequence.
To generate the pMYs-Myc-LRFN4-CT-IG plasmid, sequences
encoding the Myc tag (EQKLISEEDL) and the cytoplasmic region
of LRFN4 (540–635 a.a.) were ampliﬁed by PCR from pMYs-
LRFN4-GFP plasmid, and subcloned into PacI/NotI sites of pMYs-
IG. To generate the pMYs-LRFN4 plasmid, the LRFN4 fragment
was ampliﬁed from the pMYs-LRFN4-GFP plasmid and subcloned
into BamHI/NotI sites of pMYs. To generate the pMYs-LRFN4
DCT-GFP plasmid, an LRFN4 fragment lacking the cytoplasmic tail
of LRFN4 (1–544 a.a.) was ampliﬁed from the pMYs-LRFN4-GFP
plasmid and subcloned into BamHI/NcoI sites of pMYs-IG in-frame
with the vector’s C-terminal EGFP sequence.
2.3. Cell culture
Human embryonic kidney (HEK293T), human cervical carci-
noma (HeLa), and human breast cancer (SK-BR-3) cell lines weremaintained in DMEM supplemented with 10% FBS. Human gastric
cancer cell lines (MKN7 and MKN45), a human colon adenocarci-
noma cell line (SW480), a human pancreatic cancer cell line
(PANC-1), a human chronic myelogenous leukemia cell line
(K562), a human Burkitt’s lymphoma cell line (Ramos), a human
monocytic leukemia cell lines (THP-1 and U937), and a human T-
cell leukemia cell line (Jurkat) were maintained in RPMI-1640
medium supplemented with 10% FBS. To differentiate THP-1 cells
into macrophage-like cells, the cells were incubated with different
concentrations of PMA for speciﬁed intervals. Plat-A packaging
cells were kindly provided by Prof. Toshio Kitamura at the Univer-
sity of Tokyo and maintained in DMEM supplemented with 10%
FBS, containing 10 lg/ml puromycin and 1 lg/ml brasticidine.
Peripheral blood mononuclear cells (PBMCs) were isolated from
heparinized venous whole blood from healthy volunteers by Fi-
coll-Paque Plus density gradient separation. In accordance with
the regulations set forth by the Human Investigations Committee
of Tokyo University of Science, informed consent was obtained
from all adult volunteers. To isolate monocytes from PBMCs, the
cells were attached to a plastic dish and the non-adherent cells
were removed. To differentiate primary monocytes into macro-
phages, cells were incubated with 20 ng/ml of macrophage-colony
stimulating factor for 7 days. Human umbilical vein endothelial
cells (HUVECs) were purchased from Cell Applications Inc. and cul-
tured according to the manufacturer’s instructions.
2.4. Immunoblotting
Various cell lines were lysed in lysis buffer (50 mM Tris–HCl,
pH 7.4, 150 mM NaCl, 1% Triton X-100, 10% Glycerol, 1.5 mM
MgCl2, 1 mM EDTA, 10 mM NaF, 1 mM Na3VO4, 1% Protease Inhib-
itor Cocktail) and incubated on ice for 30 min. After centrifugation,
soluble supernatants were mixed with SDS–PAGE sample buffer
and boiled for 5 min. The proteins within each cell lysate were sep-
arated by SDS–PAGE and transferred onto PVDF membranes. The
membranes were blocked with 5% non-fat drymilk in TBS contain-
ing 0.05% Tween-20 for 1 h at room temperature. Then membranes
were incubated with anti-LRFN4 mAb (1 lg/ml, clone 3A12-7) or
anti-b-actin mAb (1:40 000 dilution) diluted in TBS containing 1%
non-fat drymilk and 0.05% Tween-20 over night at 4 C. After
washing in TBS containing 0.05% Tween-20, the membranes were
incubated with horseradish peroxidase-conjugated horse anti-
mouse IgG (100 ng/ml) for 1 h at room temperature. Immunoreac-
tive protein bands were visualized using Immobilon Western
Chemiluminescent HRP Substrate. Images were acquired with a
LAS-4000 mini (Fujiﬁlm, Tokyo, Japan).
2.5. Flow cytometry
The cells were dissociated with FACS buffer (PBS containing
3 mM EDTA and 0.4% BSA) and incubated with 10 lg/ml of anti-
LRFN4 mAb (clone 3A12-7) or isotype-matched control antibody
(anti-FLAG mAb, clone M2) for 1 h at 4 C. After the washes with
FACS buffer, the cells were incubated with 5 lg/ml of Alexa Fluor
488-conjugated donkey anti-mouse IgG for 30 min at 4 C. After
the washes with FACS buffer, the cells were analyzed using FAC-
SCalibur ﬂow cytometer equipped with CellQuest software (Becton
Dickinson, Franklin Lakes, NJ).
2.6. Retrovirus infection
Plat-A packaging cells were transiently transfected with pMYs-
IG, pMYs-LRFN4-GFP, pMYs-Myc-LRFN4-CT-IG, pMYs-LRFN4, or
pMYs-LRFN4 DCT-GFP using TransFast transfection reagent
according to the manufacturer’s instructions. Retroviral superna-
tants were harvested 48 h after transfection. To infect THP-1 cells
Fig. 2. Upregulation of LRFN4 protein in THP-1 cells following PMA stimulation. (A)
THP-1 cells were stimulated with 25 nM of PMA for 24 h. Cell lysates were prepared
and analyzed on immunoblots as described in Section 2.4. (B) THP-1 cells were
stimulated with indicated amount of PMA for 24 h. After stimulation, ﬂow
cytometry was performed as described in Section 2.5. Data are presented as the
mean ± standard error of triplicate samples. () Stained without primary Ab. (N)
Stained with isotype-matched control Ab. (d) Stained with anti-LRFN4 mAb. (C)
THP-1 cells were stimulated with 25 nM of PMA for indicated period. After
stimulation, ﬂow cytometry was performed as described in Section 2.5. Data are
presented as the mean ± standard error of triplicate samples. () Stained without
primary Ab. (N) Stained with isotype-matched control Ab. (d) Stained with anti-
LRFN4 mAb.
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LRFN4, or pMYs-LRFN4 DCT-GFP, THP-1 cells (1  106 cells/
0.5 ml/well) were centrifuged in six-well plates at 310g for 1 h
at room temperature in the presence of 1.5 ml of retroviral super-
natant supplemented with 8 lg/ml of polybrene. Plates were
placed back in a CO2 incubator at 37 C for 2 h. The retroviral
supernatant was diluted with fresh THP-1 medium (RPMI-1640
medium supplemented with 10% FBS), and the cells were allowed
to recover for 18 h. To enhance the efﬁciency of infection, the cells
were subjected to another three cycles of infection and then al-
lowed to recover for 42 h. The stable expression of GFP, LRFN4-
GFP, Myc-LRFN4-CT, LRFN4, and LRFN4 DCT-GFP were veriﬁed by
ﬂow cytometry and/or immunoblotting.
2.7. Transendothelial migration assay
HUVECs were seeded onto a 15-mm£ glass coverslip (Thermo
Fisher Scientiﬁc, Waltham, MA), which was pre-coated with 0.05%
gelatin solution, and grown in Endothelial Cell Growth Medium V2.
After these cells reached conﬂuence, they were stimulated with
10 ng/ml of IL-1b for 6 h. For analysis of the effect of anti-LRFN4
mAb, THP-1 cells expressing GFP were stimulated with 25 nM of
PMA for 48 h, pre-incubated with 10 lg/ml of anti LRFN4 mAb
(clone 3H12A) or isotype-matched control IgG (mouse IgG2 isotype
control antibody) for 30 min and then seeded onto the HUVEC-
layer. For analysis of the effect of LRFN4-CT overexpression, THP-
1 cells expressing GFP alone or Myc-LRFN4-CT were stimulated
with 25 nM of PMA for 48 h and then seeded onto the HUVEC-
layer. After 2 h of co-culture, the cells were ﬁxed with 3% formal-
dehyde for 20 min at room temperature. Using phase contrast
microscopy, THP-1 cells adhering on top of the HUVEC-layer were
observed as bright cells, and the migrating THP-1 cells were ob-
served as ﬂat, dark, large cells, in which nuclei and granules could
be easily observed, as described previously [12,13]. In addition,
GFP ﬂuorescence images were used for the identiﬁcation of THP-
1 cells. The migration ratios were calculated from the numbers of
migratory and adherent THP-1 cells.
2.8. Cell elongation assay
Anti-LRFN4 mAb (clone 3A12-7) was coated onto 15-mm £
glass coverslips (Matsunami Glass Industries, Osaka, Japan) at a
concentration of 10 lg/ml over night at 4 C, and then unbound
antibodies were washed out with THP-1 medium (RPMI-1640
medium supplemented with 10% FBS). For analysis of the effect
of exogeneous expression of LRFN4-GFP, LRFN4, or LRFN4 DCT-
GFP, THP-1 cells expressing LRFN4-GFP, LRFN4, or LRFN4 DCT-
GFP were seeded onto anti-LRFN4 mAb-coated coverslips. For anal-
ysis of the effect of Latrunculin A, THP-1 cells expressing LRFN4-
GFP were pre-treated with different concentrations of Latrunculin
A for 30 min and then seeded onto anti-LRFN4 mAb-coated cover-
slips. After a speciﬁed incubation time, cells were ﬁxed with 3%
formaldehyde for 20 min at room temperature. The ratio ofFig. 1. LRFN4 expression in several human cell lines. Lysates of several cell lineelongated cells to total adherent cells was calculated by micro-
scopic observation as described previously [13,14]; elongated cells
were deﬁned as cells with protrusions that were at least 2 times
longer than the width of the cell body.s were prepared and analyzed on immunoblots as described in Section 2.4.
Fig. 3. LRFN4 protein expression in primary monocytes and macrophages. (A)
PBMCs were isolated as described in Section 2.3, and ﬂow cytometry was performed
as described in Section 2.5. LRFN4 protein expression in lymphocytes or monocytes
was analyzed by gating the area of each population in forward scatter-side scatter
plots. Dotted line, stained without primary Ab. Solid line, stained with isotype-
matched control Ab. Heavy line, stained with anti-LRFN4 mAb. (B) Monocytes were
isolated and induced to differentiate into macrophage as described in Section 2.3.
Immunoblot analysis was performed as described in Section 2.4.
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The cells were ﬁxed with 3% formaldehyde for 20 min at room
temperature. After the cells were washed with PBS three times,Fig. 4. LRFN4-GFP protein localization in PMA-stimulated THP-1 cells. THP-1 cells stably
cells were seeded onto a 15-mm£ coverslip and stimulated with 25 nM of PMA for the in
phalloidin (red) and Hoechst 33342 (blue) as described in Section 2.9. The cells were obse
indicated the cells which formed typical lamellipodia and podosomes, respectively. Scalthey were permeabilized with 0.1% Triton X-100 for 5 min at room
temperature. After cells were washed with PBS three times again,
they were incubated with rhodamine-conjugated phalloidin
(250 ng/ml) and Hoechst 33342 (1 lg/ml) for 1 h at room temper-
ature. The stained cells were washed with PBS three times and
mounted onto slides in ProLong Gold Antifade Reagent. The cells
were observed using an Axiovert 200M ﬂuorescent microscope
(Carl Zeiss MicroImaging, Jena, Germany). Images were acquired
with a cooled CCD camera using AxioCAMMRm (Carl Zeiss MicroI-
maging), and the images were processed with AxioVision software
(Carl Zeiss MicroImaging). The cells were also observed using an
LSM 5 Exciter confocal laser scanning microscope (Carl Zeiss
MicroImaging), and the confocal images were processed with
LSM Image Browser software (Carl Zeiss MicroImaging).3. Results
3.1. Protein expression proﬁle of LRFN4 in various human cell lines
It is generally accepted that the expression of LRFN family
members is largely restricted to neural tissue [1,2]. However, our
unpublished data indicated that mRNAs of LRFN family members
were expressed in a wide variety of normal human tissues and can-
cer cell lines. Because LRFN4 mRNA showed a very wide expressionexpressing LRFN4-GFP fusion protein were generated as described in Section 2.6. The
dicated period. After stimulation, the cells were stained with rhodamine-conjugated
rved using confocal laser scanning microscopy. Arrowheads and arrows in the image
e bar, 20 lm.
Fig. 5. LRFN4 signaling is involved in transendothelial migration of PMA-stimulated
THP-1 cells. (A) A phase-contrast and GFP ﬂuorescent images of a co-culture of
PMA-stimulated THP-1 cells expressing GFP and IL-1b-treated HUVECs. Represen-
tative images of adherent THP-1 cells on HUVEC-layer, partially migratory cells, and
fully migratory THP-1 cells beneath HUVEC-layer are indicated by arrowheads,
hatched arrows, and open arrows, respectively. Scale bar, 20 lm. (B) PMA-
stimulated THP-1 cells stably expressing GFP were pre-incubated with anti-LRFN4
mAb and then seeded onto IL-1b-treated HUVEC-layer as described in Section 2.7.
The migration ratios were calculated from the numbers of migrated and adherent
THP-1 cell as described in Section 2.7. Data are presented as the mean ± standard
error. ⁄P = 0.007. (C) PMA-stimulated THP-1 cells expressing GFP (Mock) and Myc-
LRFN4 cytoplasmic region (LRFN4-CT) were seeded onto IL-1b-treated HUVEC-layer
as described in Section 2.7. The migration ratios were calculated from the numbers
of migrated and adherent THP-1 cell as described in Section 2.7. Data are presented
as the mean ± standard error. ⁄P < 0.0001.
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protein expression of LRFN4, we generated monoclonal antibodies
to human LRFN4 protein. Because we used the cells expressing the
extracellular region of LRFN4 as the immunogen, all anti-LRFN4
mAbs generated by us recognized extracellular region of LRFN4
protein. Among these antibodies, only clone 3A12-7 which recog-
nized the region between IgC2 and FNIII domain of LRFN4 protein
(377–399 a.a.) could be used for immunoblot analysis (Fig. S2).
Immunoblot analysis using clone 3A12-7 revealed that LRFN4 pro-
tein was expressed in a wide variety of human cancer and leuke-
mia cell lines (Fig. 1). Two major LRFN4 protein bands were
detected in several cell lines (100 and 70 kDa, Fig. 1). The 100-
kDa band, which appeared to be N-glycosylated [1,2], was promi-
nent in the gastric cancer MKN7 cells, Burkitt’s lymphoma Ramos
cells, and T-cell leukemia Jurkat cells (Fig. 1). The 70-kDa band
was prominent in breast cancer SK-BR-3 cells and two monocytic
leukemia cell lines, THP-1 and U937 (Fig. 1).
3.2. LRFN4 protein expression in monocytic cells is upregulated
following macrophage differentiation
Human monocytic leukemia THP-1 cells can differentiate into
macrophage-like cells following PMA stimulation [15–18].Immunoblot and ﬂow cytometry analyses revealed that LRFN4 pro-
tein expression in THP-1 cells was upregulated following PMA
stimulation in a dose-dependent manner (Fig. 2A and B). The
expression of LRFN4 protein reached a maximum at day 2 and then
decreased gradually (Fig. 2C).
Next, we examined LRFN4 protein expression in primary hema-
topoietic cells. Flow cytometry analysis revealed that 10% of PBMCs
expressed LRFN4 protein (Fig. 3A, upper), and most LRFN4-positive
cells were monocytes (Fig. 3A, lower). When monocytes were in-
duced to differentiate into macrophage with macrophage-colony
stimulating factor treatment, the expression of LRFN4 protein
was upregulated (Fig. 3B).
We also examined the localization of LRFN4 protein in THP-1
cells following PMA stimulation. Because our anti-LRFN4 mAbs
were not suitable for immunoﬂuorescent staining of ﬁxed cells,
we generated THP-1 cells that stably expressed LRFN4-GFP fusion
protein using retrovirus infection. Without PMA stimulation,
LRFN4-GFP mainly localized at the cell surface of THP-1 cells
(Fig. 4, day 0). After PMA stimulation, the cells changed shape
and became elongated or ﬂattened, and actin-rich structures (i.e.,
lamellipodia and podosomes) were formed (Fig. 4, arrowhead
and arrow). LRFN4-GFP tended to localize at lamellipodia, which
were formed at intermediate time points during PMA stimulation
(Fig. 4, arrowhead). These results indicated that LRFN4 may be in-
volved in cell migration.
3.3. LRFN4 signaling is involved in transendothelial migration of
monocytes/macrophages
We hypothesized that LRFN4 signaling was involved in the
migration of monocytes/macrophages into areas of inﬂammation.
To evaluate this hypothesis, we developed a co-culture of PMA-
stimulated THP-1 cells and IL-1b-treated HUVECs. Using phase
contrast microscopy, THP-1 cells adhering on the HUVEC-layer
were observed as bright cells (Fig. 5A, arrowheads); in contrast,
migrating THP-1 cells were observed as ﬂat, dark, large cells, in
which nuclei and granules could be easily observed (Fig. 5A, open
arrows). We ﬁrst examined the effect of anti-LRFN4 mAb on THP-1
behavior. When PMA-stimulated THP-1 cells were pre-incubated
with anti-LRFN4 mAb (clone 3H12A), migration was signiﬁcantly
inhibited (Fig. 5B). We also examined the effect of overexpression
of the LRFN4 cytoplasmic region (LRFN4-CT), which is a putative
inhibiter of LRFN4 signaling in PMA-stimulated THP-1 cells that
express endogenous LRFN4. The migration of PMA-stimulated
THP-1 cells expressing LRFN4-CT was signiﬁcantly inhibited com-
pared with control (Fig. 5C). These results indicated that LRFN4 sig-
naling was involved in transendothelial migration of monocytes/
macrophages.
3.4. LRFN4 signaling induces cell elongation of monocytic cells via
actin cytoskeleton reorganization
We investigated whether LRFN4 signaling induced morpholog-
ical changes, including cell polarity, in monocytic cells by reorga-
nizing the actin cytoskeleton. To avoid non-speciﬁc adhesive
effects, we used THP-1 cells expressing LRFN4-GFP protein without
PMA stimulation. When the cells were seeded onto coverslips pre-
coated with anti-LRFN4 mAb (clone 3A12-7), cell polarization and
highly elongated morphologies were observed (Fig. 6A). The fre-
quency of elongated THP-1 cells expressing LRFN4-GFP reached
at plateau after 60 min of stimulation (Fig. 6B). We also compared
the elongation ratio of THP-1 cells expressing LRFN4-GFP with that
of THP-1 cells expressing exogenous LRFN4. There was no differ-
ence in the elongation ratio between these cells, which indicated
that the C-terminal GFP tag did not disrupt the function of the
C-terminal PDZ-binding domain or that C-terminal PDZ-binding
Fig. 6. Stimulation with immobilized anti-LRFN4 mAb induces cell elongation of THP-1 cells via reorganization of the actin cytoskeleton. (A) THP-1 cells stably expressing
LRFN4-GFP were stimulated with immobilized anti-LRFN4 mAb for 2 h as described in Section 2.8, and differential interference images were acquired. Scale bar, 20 lm. (B)
THP-1 cells stably expressing LRFN4-GFP were stimulated with immobilized anti-LRFN4 mAb for indicated period as described in Section 2.8. The ratios of elongated cells
were calculated as described in Section 2.8. Data are presented as the mean ± standard error. (C) THP-1 cells stably expressing LRFN4-GFP (LRFN4 WT-GFP) or exogenous
LRFN4 (LRFN4 WT) were stimulated with immobilized anti-LRFN4 mAb for 1 h as described in Section 2.8. The ratios of elongated cells were calculated as described in
Section 2.8. Data are presented as the mean ± standard error. (D) THP-1 cells stably expressing LRFN4-GFP were stimulated with immobilized anti-LRFN4 mAb for 30 min
(upper) or 120 min (lower) as described in Section 2.8. The cells were stained with rhodamine-conjugated phalloidin (red) and Hoechst 33342 (blue), and observed using
confocal laser scanning microscopy as described in Section 2.9. Scale bar, 10 lm. (E) THP-1 cells stably expressing LRFN4-GFP (LRFN4 WT-GFP) or an LRFN4 mutant lacking
cytoplasmic region (LRFN4 DCT-GFP) were stimulated with immobilized anti-LRFN4 mAb for 1 h as described in Section 2.8. The ratios of elongated cells were calculated as
described in Section 2.8. Data are presented as the mean ± standard error. ⁄P < 0.0001. (F) THP-1 cells stably expressing LRFN4-GFP were pre-treated with indicated amount of
Latrunculin A and then stimulated with immobilized anti-LRFN4 mAb for 1 h as described in Section 2.8. The ratios of elongated cells were calculated as described in
Section 2.8. Data are presented as the mean ± standard error.
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Next, we observed ﬁlamentous actin in the elongated cells stimu-
lated with immobilized anti-LRFN4 mAb. The elongated cells
showed clear cell polarity with distinct membrane protrusions,
including long rod-like stem regions, lamellipodia with ﬁlamen-
tous actin, and leading edges that extended from the cell bodies,
which contained nuclei (Fig. 6D). To evaluate a connection be-
tween LRFN4 signaling and actin cytoskeleton reorganization, we
examined the effect of overexpression of the LRFN4 mutant lacking
cytoplasmic region (LRFN4 DCT). When THP-1 cells expressing
LRFN4 DCT were seeded onto anti-LRFN4 mAb-coated coverslips,
elongated morphologies were rarely observed (Fig. 6E). We also
found that pre-treatment with Latrunculin A, a speciﬁc inhibitor
of actin polymerization, inhibited LRFN4-mediated elongation of
THP-1 cells in a dose-dependent manner (Fig. 6F). These results
indicated that LRFN4 signaling induced elongation of THP-1 cells
via actin cytoskeleton reorganization.4. Discussion
In the present study, we found that LRFN4 was expressed in a
wide variety of human cancer and leukemia cell lines. In monocytic
cells, LRFN4 expression was upregulated following macrophage
differentiation. We also demonstrated that LRFN4 signaling was in-
volved in monocyte/macrophage transendothelial migration and
morphological changes, including the induction of cell polarity,
via reorganization of the actin cytoskeleton.
Previous studies have reported that the expression and function
of LRFN family members are largely restricted to neural tissue [1–
4]. However, a few reports indicated that LRFN family members
were expressed and functioned in non-neural tissues [19,20]. Some
reports suggested that LRFN1 was involved in pancreatic cancer
cell survival [19] and that LRFN2 was involved in erythropoiesis
[20]. LRFN4 protein showed wider expression proﬁle than the
other LRFN proteins, suggesting that LRFN4 might function in var-
ious types of cells including cancer, leukemia and normal cells.
It is widely recognized that monocytes and macrophages are a
heterogeneous population [6]. Primary monocytes show not only
morphological heterogeneity but also differential expression pro-
ﬁle of cell-surface markers, such as CD14 (part of the receptor for
lipopolysaccharide) and CD16 (Fc c receptor III) [6]. Although fur-
ther analyses are required to reveal which monocytes express
LRFN4, our unpublished data indicated that both CD14hi and
CD14dim monocytes express LRFN4. On the basis of T helper type
1 (Th1) and Th2 polarization, the two types of polarized macro-
phage are recognized M1 (classic) and M2 (alternative) macro-
phages [21,22]. M1 macrophages produce proinﬂammatory
cytokines, mediate resistance to pathogens, and contribute to tis-
sue destruction [21–23]. In contrast, M2 macrophages produce
anti-inﬂammatory cytokines and promote tissue repair [21–23].
Recent reports indicate that PMA-stimulated THP-1 cells and mac-
rophage-colony stimulating factor-treated primary monocytes ex-
hibit M2-like phenotypes, but are not fully polarized [21,22,24,25].
It is unclear whether LRFN4 plays roles in M1-polarized macro-
phages, but LRFN4 protein may be expressed and may function
in M2-polarized macrophages.
Chemokine-mediated integrin activation of monocytes/macro-
phages and their subsequent ﬁrm adhesion to the endothelium
are essential events during transendothelial migration [7–
9,11,26,27]. Although it is unclear whether LRFN4 signaling affects
chemokine- and integrin-dependent processes, our results demon-
strated that stimulation with immobilized anti-LRFN4 mAb in-
duced elongation of THP-1 cells that expressed LRFN4-GFP
without any other stimulation. Thus, the signaling cascade that in-
duces LRFN4-mediated transendothelial migration may differ fromchemokine- and integrin-dependent processes. Monocytes/macro-
phages must migrate through basal membranes and within inter-
stitial tissues after they migrate through the endothelium to
reach tissue sites, and an actin-rich structure, the podosome, plays
roles in these processes, which together encompass tissue inﬁltra-
tion [11,28]. Our results indicated that LRFN4 signaling was in-
volved in transendothelial migration rather than tissue inﬁltration.
Our results showed that both N- and C-termini of the LRFN4 pro-
tein play roles in transendothelial migration and morphological
polarity formation ofmonocytes/macrophage. LRFN family proteins
form heteromeric and homomeric complexes in heterologous cells
[5]. Moreover, antibody against the LRR region of LRFN proteins
inhibitednotonly transassociationbetweenLRFN3-expressingcells,
but also neurite outgrowth [4,5]. Therefore, other LRFN familymem-
bers that are upregulated in HUVECs following IL-1b treatmentmay
bind to LRFN4 protein during endothelial migration. Alternatively,
secreted and cleaved fragments of adhesion molecules may bind to
LRFN4, as seen with neural cell adhesion molecule (NCAM) and Slit
[4,5,29–31]. In primary hippocampal neurons, transfection of
LRFN1, 2, or 4 constructs which lacked PDZ-binding domain attenu-
ate the neurite outgrowth facilitated by exogeneous full-length
LRFN family members [2–4]. Furthermore, there are other putative
protein–protein interactionmotifs in the LRFN4 cytoplasmic region,
including 14-3-3 domain binding motifs (RXXpS; 582–585 a.a. and
607–610 a.a.). It is unclear whether PDZ-binding domain was in-
volved in the elongation of THP-1 cells, unknown molecules that
interactwith the LRFN4cytoplasmic regionmay regulate transendo-
thelial migration and morphological changes, including the induc-
tion of cell polarity, in monocytes/macrophages.
5. Conclusions
In this study, we found that LRFN4 was expressed in a wide
variety of human cancer and leukemia cell lines. We also found
that THP-1 cells and primary monocytes expressed LRFN4 and that
the LRFN4 expression in these cells was upregulated following
macrophage differentiation. Furthermore, we demonstrated that
LRFN4 signaling regulated both PMA-stimulated THP-1 cells
migration underneath IL-1b-treated HUVEC-layers and elongation
of THP-1 cells via actin cytoskeleton reorganization. The ﬁndings
reported here indicate that LRFN4 protein has a novel functional
role in monocyte/macrophage migration. Further studies that ex-
plore the contribution of LRFN4-mediated migration and morpho-
logical changes, including establishment of cell polarity, in
monocytes/macrophages will provide valuable information for
understanding the role of LRFN4 in the regulation of monocyte/
macrophage functions.
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